0001209191-20-034985.txt : 20200608 0001209191-20-034985.hdr.sgml : 20200608 20200608163123 ACCESSION NUMBER: 0001209191-20-034985 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200604 FILED AS OF DATE: 20200608 DATE AS OF CHANGE: 20200608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANEKO YASUNORI CENTRAL INDEX KEY: 0001277503 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38419 FILM NUMBER: 20949488 MAIL ADDRESS: STREET 1: 509 ROEHAMPTON CITY: HILLS BOROUGH STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 694-6200 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-04 0 0001724521 Arcus Biosciences, Inc. RCUS 0001277503 KANEKO YASUNORI C/O ARCUS BIOSCIENCES, INC. 3928 POINT EDEN WAY HAYWARD CA 94545 1 0 0 0 Common Stock 2020-06-04 4 A 0 3000 0.00 A 3000 D Common Stock 2020-06-05 4 M 0 35000 7.99 A 38000 D Common Stock 505050 I By Kaneko Capital, LLC Common Stock 252524 I By Kaneko Investments, LLC Common Stock 96948 I By Trust Stock Option (Right to Buy) 30.05 2020-06-04 4 A 0 14000 0.00 A 2030-06-03 Common Stock 14000 14000 D Stock Option (Rights to Buy) 7.99 2020-06-05 4 M 0 35000 0.00 D 2020-06-04 2029-06-05 Common Stock 35000 0 D Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Represents the exercise of options to purchase common stock by the reporting person. No shares were sold by the reporting person, and the shares received upon the exercise of such options are subject to a lock-up agreement with the underwriters for the Company's recent public offering. The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. /s/ Carolyn Tang, Attorney-in-Fact 2020-06-08